Antimicrobials | PediCap

Early oral step-down to amoxicillin is safe and effective for children hospitalised with severe community-acquired pneumonia: the PediCAP trial

2024

Authors: Musiime V on behalf of the PediCAP trial team

Presented at: ESCMID Global 2024

Read More

Navigating the COVID-19 Pandemic for Participant Recruitment and Follow-up: Experiences from the PediCAP Clinical Trial Consortium

2023

Authors: Kiggwe A, Nalwanga D, Tagoola A, Madhi S, Moore PD, Archary M, Mulenga V, Mujuru AH, Sacarlal J, Buck WC, Sidat M, Nguyen H, Haque F, Dennis E, Clements M, Murphy B, Spittle B, Viero F, Bielicki J, Musiime V,  Sharland M

Presented at: The EDCTP Forum 2023

Read more

External factors affecting recruitment in a global paediatric pneumonia trial: lessons learned from PediCAP

2023

Authors: Pillay K, Archary M, Bielicki J, Buck WC, Clements M, Dennis E, Goelen J, Haque F, Kiggwe A, Madhi S, Moore PD, Mujuru AH, Mulenga V, Murphy B, Musiime V, Nalwanga D, Nguyen H, Sacarlal J, Sidat M, Spittle B, Tagoola A, Viero F, Sharland M

Presented at: The EDCTP Forum 2023

Read more

Building a national network for inpatient pediatric clinical research in Mozambique 

2023

Authors: Sacarlal WJ, Buck C, Passanduca A, Macassa E, Saíde A, Chhaganlal K, Gafur M, Seni A, Machava S, Martins L, Issa F, Macanze E, Manjate N, Chaúque S, Langa S, Sidat M, Cassia U, Salimo A, Mavume C, Massitela C, Maieca A, Joaquim W, Martins S, Adriano Q, Zandamela M, Bramugy J, Bassat Q, Moraleda C, Tagarro A, Sharland M, Rojo P

Presented at: The EDCTP Forum 2023

Read more

Receipt of intravenous co-amoxiclav challenged eligibility screening for the PediCAP Trial in Johannesburg, South Africa 

2023

Authors: Moore PD, Waggie Z, Nkosi S, Nkosi L, Kumalo N, Nkumana N, Zulu N, Dangor Z, Sharland M, Madhi S

Presented at: The EDCTP Forum 2023

Read more

Global estimates of the relative pediatric consumption and cost of oral amoxicillin and amoxicillin plus clavulanic acid

2021

Authors: G. A. Levine, M. Sharland, S. Ellis, Y. Ferrisse, C. Loze, Y. Hsia, G. Fink, J. Bielicki; for the PediCAP project

Published in: ECCMID 2021

 

Abstract

Background: Amoxicillin and co-amoxiclav are commonly used antibiotics for community-acquired infections in young children. Both are classified as Access antibiotics for pediatric respiratory infections in the WHO EMLc.

1